MedicinemedRxiv
Ranked by formulaVerdict: NotableLong-read sequencing and benchmarking of saliva against blood for genomic variant detection in autism
Autism is highly heritable, yet many cases remain genetically unsolved even after short-read sequencing (SRS).
Key numbers
- 28X to 24
- 34X in blood samples
- 10% versus 0.005% of reads
Caveats
- Not randomized: its findings are associations.
- Preprint; not yet peer reviewed.
VerdictWorth a reader's time today.
Abstract
Autism is highly heritable, yet many cases remain genetically unsolved even after short-read sequencing (SRS). Long-read sequencing (LRS) increases sensitivity for pathogenic variant discovery, especially for complex structural variants (SVs) in repetitive regions missed by SRS. However, LRS largely relies on blood-derived DNA; whether saliva can support genome-wide LRS at population scale remains to be seen. We report the first systematic evaluation of saliva-derived DNA for genome-wide LRS in autism, benchmarking 105 new saliva samples against 68 new blood samples and integrating 189 previously published LRS blood samples to expand the autism cohort and improve ultra-rare pathogenic variant discovery. A matched blood-saliva quad provided direct comparisons of variant detection between sample sources. Saliva samples contained substantially more nonhuman DNA than blood (mean 10% versus 0.005% of reads), reducing mean effective genome coverage from an estimated 28X to 24X after removal of nonhuman reads, compared with 34X in blood samples. Despite this reduction, saliva and blood samples yielded comparable numbers of validated (22,591 versus 23,064) and rare (209 versus 213) SVs per sample, which was also observed in the quad when matching coverage. Saliva LRS identified four new pathogenic and likely pathogenic variants missed by SRS. We report variants affecting MECP2, DNMT3A, CHD8, LMBRD2, POGZ, and PHF3; four additional candidates with potential relevance to autism; and an increase of diagnostic yield of 9-18%. Saliva-derived DNA support blood-comparable discovery of pathogenic variants missed by SRS, including SVs, with increased sequencing coverage compensating for nonhuman DNA contamination and reduced assembly contiguity, thus showing saliva DNA collection as a feasible strategy for large-scale LRS studies of patients and population-scale sequencing of cohorts.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ███░░ 3 | 10% | A method or resource many groups across the field will adopt within a year. |
| Magnitude | ████░ 4 | 20% | A qualitative jump: a capability or regime that did not exist before. |
| Evidence | ███░░ 3 | 32% | Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data. |
| Novelty | ██░░░ 2 | 8% | A new combination of known ideas. |
| Trajectory | ██░░░ 2 | 5% | Some room to improve with obvious engineering. |
| Stakes | ██░░░ 2 | 25% | Benefits a professional community (practitioners, clinicians, engineers). |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: method (we report); gains (x-fold, relative gain, versus baseline); novelty (discovery); verification (error bars, experimental validation); scale (scalable); stakes (genetic disease). Red flags: not randomized; derivative (comparative study).
How the score was computed
- Merit
- 5.6 / 10
- Adjusted merit
- 4.8 / 10
- Attention
- 0%
- Freshness
- 92%
- Citations0 (reference 20, via semantic-scholar, Oct 14, 2026, 06:17 UTC)